Novo Nordisk’s Difficult Week Wipes Out Remaining Gains Driven by Wegovy

Novo Nordisk's Weight Loss Boom Fades Amid Market Setbacks

The remarkable rise in Novo Nordisk A/S shares, fueled by the popularity of its weight loss treatments, has come to an end. This week, the Danish pharmaceutical company's stock erased the last of the gains made since the 2021 U.S. approval of its obesity drug, Wegovy, after a new generation injection failed to outperform its main competitor.

Top Stories from Bloomberg

Novo Nordisk shares have dropped 21% this week, marking their largest weekly decline since August. This surpasses the 20% drop earlier in the month, which followed a bleak sales outlook.

This downturn concludes a volatile five-year period for Novo Nordisk, during which the company enjoyed a surge in stock value thanks to its dominance in the obesity drug sector. However, less than two years have undone those fivefold gains. Now, CEO Mike Doustdar faces growing pressure to expand beyond the diabetes and obesity markets that have defined the company for thirty years.

Wegovy Pills Take Center Stage

According to Intron Health analyst Naresh Chouhan, Novo Nordisk's future now hinges on the success of its Wegovy pills. The recent launch has been one of the most successful in pharmaceutical history, with over 240,000 Americans already using the medication, Doustdar reported.

Chouhan warned, “If there are any indications that this strong start is slowing, we anticipate the stock will continue to lose value.”

Analysts Downgrade Novo Nordisk After Disappointing Results

For some optimistic analysts, the underwhelming results from Novo’s next-generation obesity shot, CagriSema, were the tipping point, leading five analysts to downgrade the stock. Emmanuel Papadakis of Deutsche Bank AG lowered his rating to hold, stating that the results significantly weaken the investment case for the drug.

Richard Vosser of JPMorgan Chase & Co. also downgraded the stock to neutral, suggesting that recent developments could limit the drug’s commercial prospects.

Competitive Pressures Intensify

Despite Novo’s obesity injection achieving a 20.2% weight loss—close to Eli Lilly & Co.’s 23.6% with tirzepatide—doubts remain about Novo’s ability to maintain its lead in the obesity treatment market. Doustdar emphasized the positive results during an investor call, even as some analysts questioned whether CagriSema is becoming outdated.

With competitors developing drugs that require less frequent dosing and offer greater effectiveness, Novo Nordisk’s capacity to sustain its obesity drug business beyond the 2032 patent expirations is under scrutiny. HSBC Holdings Plc analyst Rajesh Kumar noted that this issue could spark further debate among investors.

©2026 Bloomberg L.P.